Advertisement
News
Advertisement

Anacor Pharmaceuticals Appoints New CEO

Wed, 03/19/2014 - 9:54am
Associated Press

PALO ALTO, Calif. - Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced that the company’s Board of Directors has appointed Paul L. Berns, Anacor’s Chairman of the Board of Directors, to assume the role of President and Chief Executive Officer, effective immediately. Mr. Berns succeeds David P. Perry who has served as Anacor’s President and Chief Executive Officer since 2002.

Mr. Berns has over 20 years of industry experience as an executive in biotechnology and pharmaceutical companies. He most recently served as the President and Chief Executive Officer of Allos Therapeutics prior to its acquisition by Spectrum Pharmaceuticals, Inc. in 2012.

“We appreciate David’s commitment to Anacor and the many contributions he has made over the past 12 years to help build Anacor into the company it is today,” said Paul Klingenstein, Chair of the Nominating and Governance Committee of the Anacor Board. “We are delighted to have attracted a proven leader of Paul’s capabilities to assume the role of CEO for the next phase of Anacor’s growth. Having served as Chairman, Paul has a deep knowledge of Anacor’s management team, strategy, partners and development pipeline, thus enabling a smooth transition. Additionally, Paul’s significant commercial and product development experience, combined with his strategic and business development expertise, makes him ideally suited to lead Anacor as we seek to achieve our goals.”

“I am honored to lead Anacor at a time when it has a number of promising product candidates,” commented Mr. Berns. “We await action by the FDA this summer on our Kerydin NDA and look forward to launching pivotal studies of AN2728 in mild-to-moderate atopic dermatitis patients. We are encouraged by the progress of our lead programs and are confident in our financial strength and commercialization prospects. I look forward to working closely with the Company’s talented team as we continue to make progress on the next steps for Kerydin and the ongoing development of AN2728.”

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading